SciSparc Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Oz Adler

Chief Executive Officer (CEO)

US$379.0k

Compensación total

Porcentaje del salario del CEO	83.1%
Permanencia del CEO	6.2yrs
Participación del CEO	n/a
Permanencia media de la dirección	6.2yrs
Promedio de permanencia en la Junta Directiva	8yrs

Actualizaciones recientes de la dirección

Recent updates

SciSparc to acquire an American food supplements and cosmetics brand in ~$20M deal

Aug 15

SciSparc board of directors to promote buyback program of up to $1M

Jul 06

SciSparc completes development of SCI-110 to treat tourette syndrome

Jun 29

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Oz Adler en comparación con los beneficios de SciSparc?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$379k	US$315k	-US$5m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	US$287k
Mar 31 2023	n/a	n/a	-US$1m
Dec 31 2022	US$549k	US$358k	-US$3m
Sep 30 2022	n/a	n/a	-US$6m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$7m
Dec 31 2021	US$297k	US$223k	-US$6m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$301k	US$188k	-US$3m
Sep 30 2020	n/a	n/a	-US$4m
Jun 30 2020	n/a	n/a	-US$5m
Mar 31 2020	n/a	n/a	-US$4m
Dec 31 2019	US$258k	US$189k	-US$5m
Sep 30 2019	n/a	n/a	-US$5m
Jun 30 2019	n/a	n/a	-US$5m
Mar 31 2019	n/a	n/a	-US$9m
Dec 31 2018	US$230k	US$184k	-US$6m

Compensación vs. Mercado: La compensación total de Oz($USD379.00K) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD673.68K).

Compensación vs. Ingresos: La compensación de Oz ha sido consistente con los resultados de la empresa en el último año.

CEO

Oz Adler (37 yo)

6.2yrs

Permanencia

US$379,000

Compensación

Mr. Oz Adler, CPA, is Independent External Director of Rail Vision Ltd since June 2022. He is Independent Director of Polyrizon Ltd. from September 2021.He has been Independent Director at Clearmind Medic...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Oz Adler	CEO & CFO	6.2yrs	US$379.00k	sin datos
Itschak Shrem	President & Director	2.4yrs	US$235.00k	0.011% $ 300.3
Adi Zuloff-Shani	Chief Technologies Officer	8.3yrs	US$296.00k	sin datos

6.2yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SPRC es experimentado (6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Itschak Shrem	President & Director	3.8yrs	US$235.00k	0.011% $ 300.3
Daniele Piomelli	Member of Scientific Advisory Board	no data	sin datos	sin datos
Elon Eisenberg	Member of Scientific Advisory Board	no data	sin datos	sin datos
James Leckman	Member of Scientific Advisory Board	8yrs	sin datos	sin datos
Joseph Tam	Member of Scientific Advisory Board	no data	sin datos	sin datos
Kirsten Müller-Vahl	Member of Scientific Advisory Board	8yrs	sin datos	sin datos
Michael Davidson	Member of Scientific Advisory Board	8yrs	sin datos	sin datos
Avi Weizman	Member of Scientific Advisory Board	8yrs	sin datos	sin datos
Michael Bloch	Member of Scientific Advisory Board	8yrs	sin datos	sin datos
Amitai Weiss	Chairman of the Board	3.8yrs	US$235.00k	0.00081% $ 22.2
Mellar Davis	Member of Scientific Advisory Board	no data	sin datos	sin datos
Amnon Shay	Independent Director	3.4yrs	sin datos	sin datos

8.0yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de SPRC se considera experimentada (7.8 años de antigüedad promedio).

SciSparc Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

SciSparc Ltd., Annual General Meeting, Aug 15, 2023

SciSparc Ltd., Annual General Meeting, Aug 11, 2022

Recent updates

SciSparc Ltd. (NasdaqCM:SPRC) signed a merger agreement to acquire remaining stake in Automax Motors Ltd (TASE:AMX).

SciSparc Ltd. Announces Successfully Dosed the First Patient in Its SCI-210 Clinical Trial At the Soroka Medical Center for Pediatric Patients

Investor sentiment deteriorates as stock falls 16%

SciSparc Ltd. Announces Enrollment of First Patient for Its Clinical Trial for Children with Autism Spectrum Disorder

Scisparc Ltd. Granted Patent for Core Technology in Multiple Jurisdictions in Europe

Investor sentiment improves as stock rises 17%

Insufficient new directors

Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder

Investor sentiment improves as stock rises 68%

SciSparc Ltd. announced that it expects to receive $20 million in funding from Yorkville Advisors Global LP

Investor sentiment deteriorates as stock falls 18%

Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Scisparc Ltd. Obesity Drug Showed Positive Results in A Pre-Clinical Trial

SciSparc Ltd. Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment

SciSparc Ltd. Announces Initiation of its Phase IIb Clinical Trial Treatments with its SCI-110, Proprietary Drug Candidate

SciSparc Ltd. Receives Patent from the Australian Patent Office for Its Reduction of Opioids Use in Pain Management Technology

SciSparc Ltd. Receives Notice of Acceptance for Its Core Technology Application for the Combinations of Cannabinoids and N-Acylethanolamines

Investor sentiment improves as stock rises 85%

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Ltd. announced that it expects to receive $5.018281 million in funding

SciSparc Ltd. announced that it expects to receive $5.018281 million in funding

SciSparc Ltd. Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S

SciSparc Ltd., Annual General Meeting, Aug 15, 2023

SciSparc Ltd. Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

Scisparc Ltd. Announces Irb Approval to Conduct Its Phase Iib Trial in Tourette Syndrome

New major risk - Share price stability

Capital Point Ltd. Files Suit Against SciSparc Ltd

SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center

SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial

Scisparc Announces Positive Study Results with Sci-210, A Cannabidiol-Based Treatment for Epilepsy

SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

SciSparc Ltd. Announces Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation

Scisparc Ltd. Announces its Scisparc Nutraceuticals Inc. Successfully Launches New Keto Gummies Apple Cider Vinegar Product

SciSparc Announces Receipt of Nasdaq Minimum Bid Price Notification

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of Its Psychedelic-Based Pharma Collaboration with Clearmind Medicine Inc

SciSparc to acquire an American food supplements and cosmetics brand in ~$20M deal

SciSparc Ltd. Receives Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders

SciSparc Ltd. Announces Israeli Ministry of Health Approval to Conduct Its Clinical Trial in Autism Spectrum Disorder

SciSparc Ltd., Annual General Meeting, Aug 11, 2022

SciSparc Ltd. (NasdaqCM:SPRC) announces an Equity Buyback for $1 million worth of its shares.

SciSparc board of directors to promote buyback program of up to $1M

SciSparc Ltd. Completes Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study in Tourette Syndrome

SciSparc completes development of SCI-110 to treat tourette syndrome

SciSparc Ltd. Announces Ethics Committee Approval to Conduct Clinical Trial in Autism Spectrum Disorder

Clearmind Medicine Inc. and SciSparc Ltd Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors

SciSparc Ltd. announced that it expects to receive $10 million in funding

SciSparc Ltd. Announces Ethics Committee Approval to Conduct A Phase IIb Trial in Tourette Syndrome

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

SciSparc Ltd. and Clearmind Medicine Inc. Collaborations Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors

SciSparc Ltd. Announces Recruitment of First Patient for Its Phase IIa Clinical Trial in Alzheimer's Disease

SciSparc Ltd. Ordinary Shares Deleted from Other OTC

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad